Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women

References

• COVID-19 coronavirus pandemic. Worldometer; 2023 Apr 15. https://www.worldometers.info/coronavirus/.
   Google Scholar
• Phoswa WN, Khaliq OP. Is pregnancy a risk factor of COVID-19? Eur J Obstet Gynecol Reprod Biol. 2020;252:605–9. doi:10.1016/j.ejogrb.2020.06.058.
   PubMed Web of Science ®Google Scholar
• Riley LE. mRNA Covid-19 vaccines in pregnant women. N Engl J Med. 2021;384(24):2342–3. doi:10.1056/NEJMe2107070.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. COVID-19 vaccines in pregnancy. Trends Mol Med. 2022;28(8):662–80. doi:10.1016/j.molmed.2022.04.012.
   PubMed Web of Science ®Google Scholar
• Oakes MC, Kernberg AS, Carter EB, Foeller ME, Palanisamy A, Raghuraman N, Kelly JC. Pregnancy as a risk factor for severe coronavirus disease 2019 using standardized clinical criteria. Am J Obstet Gynecol MFM. 2021;3(3):100319. doi:10.1016/j.ajogmf.2021.100319.
   PubMed Web of Science ®Google Scholar
• Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, Roggero P, Prefumo F, Do Vale MS, Cardona-Perez JA, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 Infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175(8):817–26. doi:10.1001/jamapediatrics.2021.1050.
   PubMed Web of Science ®Google Scholar
• Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, Zhou D, Coomar D, Sheikh J, Lawson H, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi:10.1136/bmj.m3320.
   PubMed Web of Science ®Google Scholar
• Januszek SM, Faryniak-Zuzak A, Barnaś E, Łoziński T, Góra T, Siwiec N, Szczerba P, Januszek R, Kluz T. The approach of pregnant women to vaccination based on a COVID-19 systematic review. Medicina. 2021;57(9):977. doi:10.3390/medicina57090977.
   PubMedGoogle Scholar
• Bookstein Peretz S, Regev N, Novick L, Nachshol M, Goffer E, Ben‐David A, Asraf K, Doolman R, Levin EG, Regev Yochay G, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obst Gyn. 2021;58(3):450–6. doi:10.1002/uog.23729.
   PubMed Web of Science ®Google Scholar
• Kalafat E, Heath P, Prasad S, Pat O, Khalil A. COVID-19 vaccination in pregnancy. Am J Obstet Gynecol. 2022;227(2):136–47. doi:10.1016/j.ajog.2022.05.020.
   PubMed Web of Science ®Google Scholar
• WHO. Coronavirus disease (COVID-19): Vaccines. World Health Organization; 2022. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines.
   Google Scholar
• The American College of Obstetricians and Gynecologists. ACOG and SMFM recommend COVID-19 vaccination for pregnant individuals. The American College of Obstetricians and Gynecologists; 2021. https://www.acog.org/news/news-releases/2021/07/acog-smfm-recommend-covid-19-vaccination-for-pregnant-individuals#:~:text=%E2%80%9CACOG%20is%20recommending%20vaccination%20of,complications%2C%20and%20because%20it%20is.
   Google Scholar
• The Royal College of Obstetricians & Gynaecologists. Coronavirus (COVID-19) infection in pregnancy. Royal College of Obstetricians & Gynaecologists; 2022. p. 1–61. https://www.rcog.org.uk/guidance/coronavirus-covid-19-pregnancy-and-women-s-health/coronavirus-covid-19-infection-in-pregnancy/.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–22. doi:10.1016/S0140-6736(21)01429-X.
   PubMed Web of Science ®Google Scholar
• Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):200. doi:10.1186/s12916-022-02397-y.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385(7):585–94. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Prasad S, Kalafat E, Blakeway H, Townsend R, O’Brien P, Morris E, Draycott T, Thangaratinam S, Le Doare K, Ladhani S, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun. 2022;13(1):2414. doi:10.1038/s41467-022-30052-w.
   PubMed Web of Science ®Google Scholar
• Badell ML, Dude CM, Rasmussen SA, Jamieson DJ. Covid-19 vaccination in pregnancy. bmj. 2022;378:e069741. doi:10.1136/bmj-2021-069741.
   PubMedGoogle Scholar
• Liu X, Shaw RH, Stuart AS, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856–69. doi:10.1016/S0140-6736(21)01694-9.
   PubMed Web of Science ®Google Scholar
• Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K, et al. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: an open-label randomized study in healthy Thai adults. Hum Vaccin Immunother. 2022;18(6):2091865. doi:10.1080/21645515.2022.2091865.
   PubMed Web of Science ®Google Scholar
• Powell AA, Power L, Westrop S, McOwat K, Campbell H, Simmons R, Ramsay ME, Brown K, Ladhani SN, Amirthalingam G. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England. Eurosurveillance. 2021;26(28):2100634. doi:10.2807/1560-7917.ES.2021.26.28.2100634.
   Web of Science ®Google Scholar
• Jara A, Undurraga EA, Zubizarreta JR, González C, Pizarro A, Acevedo J, Leo K, Paredes F, Bralic T, Vergara V, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798–e806. doi:10.1016/S2214-109X(22)00112-7.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022;386(11):1046–57. doi:10.1056/NEJMoa2116414.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, Hernán MA, Lipsitch M, Hernandez-Diaz S, Reis BY, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. 2021;27(10):1693–5. doi:10.1038/s41591-021-01490-8.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Guidance for industry toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials . 2007. p. 10. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical.
   Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh W-J, Zaki S, Murphy B, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol. 2004;78(7):3572–7. doi:10.1128/JVI.78.7.3572-3577.2004.
   PubMed Web of Science ®Google Scholar
• Houser KV, Gretebeck L, Ying T, Wang Y, Vogel L, Lamirande EW, Bock KW, Moore IN, Dimitrov DS, Subbarao K, et al. Prophylaxis with a middle east respiratory syndrome coronavirus (MERS-CoV)–specific human monoclonal antibody protects rabbits from MERS-CoV infection. J Infect Dis. 2016;213(10):1557–61. doi:10.1093/infdis/jiw080.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Technical Report Series 1004, Annex 9, 2017: World Health Organization; 2020. https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9.
   Google Scholar
• Blakeway H, Amin‐Chowdhury Z, Prasad S, Kalafat E, Ismail M, Abdallah F, Rezvani A, Amirthalingam G, Brown K, Le Doare K, et al. Evaluation of immunogenicity and reactogenicity of COVID-19 vaccines in pregnant women. Ultrasound Obst Gyn. 2022;60(5):673–80. doi:10.1002/uog.26050.
   PubMed Web of Science ®Google Scholar
• Fu W, Sivajohan B, McClymont E, Albert A, Elwood C, Ogilvie G, Money D. Systematic review of the safety, immunogenicity, and effectiveness of COVID‐19 vaccines in pregnant and lactating individuals and their infants. Int J Gynecol Obstet. 2022;156(3):406–17. doi:10.1002/ijgo.14008.
   PubMed Web of Science ®Google Scholar
• Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, Peyrot L, Allatif O, Fassier J-B, Massardier-Pilonchéry A, et al. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination. Nature. 2021;600(7890):701–6. doi:10.1038/s41586-021-04120-y.
   PubMed Web of Science ®Google Scholar
• Suphanchaimat R, Nittayasoot N, Jiraphongsa C, Thammawijaya P, Bumrungwong P, Tulyathan A, Cheewaruangroj N, Pittayawonganon C, Tharmaphornpilas P. Real-world effectiveness of mix-and-match vaccine regimens against SARS-CoV-2 delta variant in Thailand: a nationwide test-negative matched case-control study. Vaccines. 2022;10(7):1080. doi:10.3390/vaccines10071080.
   Web of Science ®Google Scholar
• Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, Chaiyakulsil C, Sinlapamongkolkul P, Tangsathapornpong A, Bunjoungmanee P, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerging Microbes Infect. 2022;11(1):585–92. doi:10.1080/22221751.2022.2037398.
   PubMed Web of Science ®Google Scholar
• Cohen G, Jungsomsri P, Sangwongwanich J, Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, et al. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines. Hum Vaccin Immunother. 2022;18(5):2052525. doi:10.1080/21645515.2022.2052525.
   PubMed Web of Science ®Google Scholar
• Gloeckner S, Hornung F, Heimann Y, Schleussner E, Deinhardt-Emmer S, Loeffler B, Zoellkau J. Newborns’ passive humoral SARS-CoV-2 immunity following heterologous vaccination of the mother during pregnancy. Am J Obstet Gynecol. 2022;226(2):261–2. doi:10.1016/j.ajog.2021.10.006.
   PubMed Web of Science ®Google Scholar
• Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Pannaraj PS, Boom JA, Sahni LC, Chiotos K, Cameron MA, et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. N Engl J Med. 2022;387(2):109–19. doi:10.1056/NEJMoa2204399.
   PubMed Web of Science ®Google Scholar
• Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Boom JA. Effectiveness of maternal vaccination with mRNA COVID-19 vaccine during pregnancy against COVID-19–associated hospitalization in infants aged< 6 months—17 states, July 2021–January 2022. Morb Mort Wkly Rep 2022; 71:264.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Soe P, Shulha HP, Valiquette L, Vanderkooi OG, Kellner JD, Muller MP, Top KA, Isenor JE, McGeer A, et al. Safety of COVID-19 vaccines in pregnancy: a Canadian national vaccine safety (CANVAS) network cohort study. Lancet Infect Dis. 2022;22(11):1553–64. doi:10.1016/S1473-3099(22)00426-1.
   PubMed Web of Science ®Google Scholar
• DeSilva M, Haapala J, Vazquez-Benitez G, Vesco KK, Daley MF, Getahun D, Zerbo O, Naleway A, Nelson JC, Williams JTB, et al. Evaluation of acute adverse events after Covid-19 vaccination during pregnancy. N Engl J Med. 2022;387(2):187–9. doi:10.1056/NEJMc2205276.
   PubMed Web of Science ®Google Scholar
• Fell DB, Dhinsa T, Alton GD, Török E, Dimanlig-Cruz S, Regan AK, Sprague AE, Buchan SA, Kwong JC, Wilson SE, et al. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. Jama. 2022;327(15):1478–87. doi:10.1001/jama.2022.4255.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, Marquez PL, Olson CK, Liu R, Chang KT, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384(24):2273–82. doi:10.1056/NEJMoa2104983.
   PubMed Web of Science ®Google Scholar
• Ellington S, Olson CK. Safety of mRNA COVID-19 vaccines during pregnancy. Lancet Infect Dis. 2022;22(11):1514–15. doi:10.1016/S1473-3099(22)00443-1.
   PubMed Web of Science ®Google Scholar
• Alghamdi AN, Alotaibi MI, Alqahtani AS, Al Aboud D, Abdel-Moneim AS. Bnt162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees. Front Med. 2021;8:760047. doi:10.3389/fmed.2021.760047.
   PubMed Web of Science ®Google Scholar
• Bae S, Lee YW, Lim SY, Lee J-H, Lim JS, Lee S, Park S, Kim S-K, Lim Y-J, Kim EO, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. 2021;36(17). doi:10.3346/jkms.2021.36.e115.
   Web of Science ®Google Scholar
• Klemis V, Schmidt T, Schub D, Mihm J, Marx S, Abu-Omar A, Ziegler L, Hielscher F, Guckelmus C, Urschel R, et al. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or Mrna-1273-boosting with homologous COVID-19 vaccine regimens. Nat Commun. 2022;13(1):4710. doi:10.1038/s41467-022-32321-0.
   PubMed Web of Science ®Google Scholar
• Clarke L, Brighton T, Chunilal SD, Lee CS, Passam F, Curnow J, Chen VM, Tran HA. Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCov19 vaccination: less severe but remains a problem. Vaccine. 2023;41(20):3285–91. doi:10.1016/j.vaccine.2023.03.071.
   PubMed Web of Science ®Google Scholar
• Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385(18):1680–9. doi:10.1056/NEJMoa2109908.
   PubMed Web of Science ®Google Scholar